Highlights of early pulmonary surfactant: Research from bench to clinic

Pneumon

Volumn 26, Issue 4, 2013, Pages 350-354

  Noutsios, Georgios T ^a   Floros, Joanna ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

AMs; Pulmonary Surfactant; RDS; SP A; UTR

Indexed keywords

LUNG SURFACTANT; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID;

AMNION FLUID; FETUS LUNG MATURITY; HUMAN; HYALINE MEMBRANE DISEASE; LUNG ALVEOLUS SURFACE TENSION; LUNG COMPLIANCE; LUNG FUNCTION; LUNG GAS EXCHANGE; LUNG PRESSURE; LUNG VOLUME; MORBIDITY; MORTALITY; PREMATURITY; RESPIRATORY DISTRESS; REVIEW;

EID: 84890679360     PISSN: 1105848X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Fujiwara T, Robertson B. Pharmacology of exogenous surfactant. In B. Robertson, L. M. G. Van Golde, and J. J. Batenburg, editors: Elsevier, Amsterdam; 1992: 561-92.
2. Griese M, Dietrich P, Reinhardt D. Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152: 1050-4.
3. Wiseman LR, Bryson HM. Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome. Drugs 1994; 48: 386-403.
4. Ainsworth SB, Beresford MW, Milligan DW, et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet 2000; 355: 1387-92.
5. Wrobel S. Bubbles, Babies and Biology: The Story of Surfactant. FASEB J 2004; 18: 1624e-.
6. K. NV. Neue auffassungen uber einen grundbegriff der atemmechanik. Die retraktionskraft der lunge, abhangig von der oberflachenspannung in den alveolen. Z Gesamt Exp Med1929: 373-94.
7. Gruenwald P. Surface tension as a factor in the resistance of neonatal lungs to aeration. Am J Obstet Gynecol 1947; 53: 996-1007.
8. Pattle RE. Properties, function and origin of the alveolar lining layer. Nature 1955; 175: 1125-6.
9. Pattle RE. Properties, function, and origin of the alveolar lining layer. Proc R Soc Lond B Biol Sci 1958; 148: 217-40.
10. Clements J. Dependence of pressure-volume characteristics of lungs on intrinsic surface active material. Am J Physiol1956: 592.
11. Clements JA. Surface tension of lung extracts. Proc Soc Exp Biol Med 1957; 95: 170-2.
12. Macklin CC. The pulmonary alveolar mucoid film and the pneumonocytes. Lancet 1954; 266: 1099-104.
13. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child 1959; 97: 517-23.
14. Enhörning G, Robertson B. Expansion patterns in the premature rabbit after tracheal deposition of surfactant. Acta Pathol Microbiol Scand A 1971; 79: 682.
15. Enhörning G, Robertson B. Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 1972; 50: 58-66.
16. King RJ, Clements JA. Surface active materials from dog lung. I. Method of isolation. Am J Physiol 1972; 223: 707-14.
17. King RJ, Clements JA. Surface active materials from dog lung. II. Composition and physiological correlations. Am J Physiol 1972; 223: 715-26.
18. King RJ, Clements JA. Surface active materials from dog lung. 3. Thermal analysis. Am J Physiol 1972; 223: 727-33.
19. Harwood JL. Lung surfactant. Biochem Soc Trans 1987; 15 Suppl: 80S-9S.
20. Adams FH, Towers B, Osher AB, Ikegami M, Fujiwara T, Nozaki M. Effects of tracheal instillation of natural surfactant in premature lambs. I. Clinical and autopsy findings. Pediatr Res 1978; 12: 841-8.
21. Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A. Microaerosol administration of synthetic beta-gamma-dipalmitoyl-L-alpha-lecithin in the respiratory distress syndrome. A preliminary report. Can Med Assoc J 1964; 90: 55-7.
22. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980; 1: 55-9.
23. Halliday HL. Overview of clinical trials comparing natural and synthetic surfactants. Biol Neonate 1995; 67 Suppl 1: 32-47.
24. Halliday HL. Surfactants: past, present and future. J Perinatol 2008; 28 Suppl 1: S47-56.
25. Robertson B CT, Johansson J, Jornvall H, Kobayashi T. Structural and functional characterization of porcine surfactant isolated by liquid-gel chromatography. Prog Resp Res1990: 237-46.
26. Phelps DS. Surfactant regulation of host defense function in the lung: a question of balance. Pediatr Pathol Mol Med 2001; 20: 269-92.
27. Floros J, Phelps DS. Pulmonary surfactant protein A; structure, expression, and its role in innate host defense. In: Nakos G, Lekka ME, eds. Surfactant-Update of Intensive Care Medicine. Ioannina, Greece: University of Ioannina; 2002: 87-102.
28. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997; 77: 931-62.
29. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999; 13: 1455-76.
30. Frerking I, Günther A, Seeger W, Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med 2001; 27: 1699-717.
31. Crouch EC. Collectins and pulmonary host defense. Am J Respir Cell Mol Biol 1998; 19: 177-201.
32. Floros J, Phelps DS. Pulmonary surfactant. In: Biebuck J, Lynch Iii C, Maze M, Saidman LJ, Yaksh TL, Zapol WM, eds. Anesthesia: Biologic Foundations: Lippincott-Raven; 1997: 1259-79.
33. Wang G, Bates-Kenney SR, Tao JQ, Phelps DS, Floros J. Differences in biochemical properties and in biological function between human SP-A1 and SP-A2 variants, and the impact of ozone-induced oxidation. Biochemistry 2004; 43: 4227-39.
34. Floros J, Thomas N. Genetic variations of surfactant proteins and lung injury. Nakos G, and Papathanasiou A, editors. Surfactant Pathogenesis and Treatment of Lung Diasease2009: 25-48.
35. Silveyra P, Wang G, Floros J. Human SP-A1 (SFTPA1) variantspecific 3' UTRs and poly(A) tail differentially affect the in vitro translation of a reporter gene. Am J Physiol Lung Cell Mol Physiol 2010; 299: L523-34.
36. Silveyra P, Raval M, Simmons B, Diangelo S, Wang G, Floros J. The untranslated exon B of human surfactant protein A2 mRNAs is an enhancer for transcription and translation. Am J Physiol Lung Cell Mol Physiol 2011; 301: L795-803.
37. Wang G, Guo X, Floros J. Differences in the translation efficiency and mRNA stability mediated by 5'-UTR splice variants of human SP-A1 and SP-A2 genes. Am J Physiol Lung Cell Mol Physiol 2005; 289: L497-508.
38. Noutsios GT, Silveyra P, Bhatti F, Floros J. Exon B of human surfactant protein A2 mRNA, alone or within its surrounding sequences, interacts with 14-3-3; role of cis-elements and secondary structure. Am J Physiol Lung Cell Mol Physiol 2013; 304: L722-35.
39. Wang G, Myers C, Mikerov A, Floros J. Effect of cysteine 85 on biochemical properties and biological function of human surfactant protein A variants. Biochemistry 2007; 46: 8425-35.
40. Huang W, Wang G, Phelps DS, Al-Mondhiry H, Floros J. Human SP-A genetic variants and bleomycin-induced cytokine production by THP-1 cells: effect of ozone-induced SP-A oxidation. Am J Physiol Lung Cell Mol Physiol 2004; 286: L546-53.
41. Wang G, Umstead T, Phelps D, Al-Mondhiry H, Floros J. The effect of ozone exposure on the ability of human surfactant protein a variants to stimulate cytokine production. Environ Health Perspect 2002; 110: 79-84.
42. Mikerov AN, Umstead TM, Huang W, Liu W, Phelps D, Floros J. SP-A1 and SP-A2 variants differentially enhance association of Pseudomonas aeruginosa with rat alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2005; 288: L150-L8.
43. Mikerov A, Wang G, Umstead T, et al. Surfactant protein A2 (SPA2) variants expressed in CHO cells stimulate phagocytosis of Pseudomonas aeruginosa more than do SP-A1 variants. Infect Immun 2007; 75: 1403-12.
44. Mikerov AN, Umstead TM, Gan X, et al. Impact of ozone exposure on the phagocytic activity of human surfactant protein A (SP-A) and SP-A variants. Am J Physiol Lung Cell Mol Physiol 2008; 294: L121-30.
45. Wang G, Guo X, Diangelo S, Thomas NJ, Floros J. Humanized SFTPA1 and SFTPA2 transgenic mice reveal functional divergence of SP-A1 and SP-A2: formation of tubular myelin in vivo requires both gene products. J Biol Chem 2010; 285: 11998-2010.
46. Tagaram HR, Wang G, Umstead TM, et al. Characterization of a human surfactant protein A1 (SP-A1) gene-specific antibody; SP-A1 content variation among individuals of varying age and pulmonary health. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1052-63.
47. Wang Y, Voelker DR, Lugogo NL, et al. Surfactant protein A is defective in abrogating inflammation in asthma. Am J Physiol Lung Cell Mol Physiol 2011; 301: L598-606.
48. Bersani I, Speer CP, Kunzmann S. Surfactant proteins A and D in pulmonary diseases of preterm infants. Expert Rev Anti Infect Ther 2012; 10: 573-84.
49. Phelps DS, Umstead TM, Quintero OA, Yengo CM, Floros J. In vivo rescue of alveolar macrophages from SP-A knockout mice with exogenous SP-A nearly restores a wild type intracellular proteome; actin involvement. Proteome Sci 2011; 9: 67.
50. Silveyra P, Floros J. Air pollution and epigenetics: effects on SP-A and innate host defence in the lung. Swiss Med Wkly 2012; 142: w13579.